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Available online 11 October 2016Introduction: Premature mortality is a major issue in Dravet syndrome (DS). To improve understanding of DS
premature mortality, we conducted a comprehensive literature search with a particular emphasis on SUDEP.
Methods:We searched PubMed, Embase,Web of Science, Cochrane, CENTRAL, CINAHL, PsycINFO, Academic Search
Premier, and ScienceDirect on the following terms: “Dravet syndrome”, “severe myoclonic epilepsy”, “SMEI”,
“mortality”, “survivors”, “prognosis”, and “death”. DS cases or cohorts studies reporting mortality were included.
Results: The search yielded 676 articles and 86 meeting abstracts. After removing duplicates and screening titles
and abstracts, full text of 73 articles was reviewed. Only 28 articles and sixmeeting abstractsmet inclusion criteria.
Five articles and four meeting abstracts were excluded, as the case(s) were also described elsewhere. After
checking the references, ﬁve additional studies were included. The 30 items reported 177 unique cases. Sudden
unexpected death in epilepsy was the likely cause in nearly half of the cases (n = 87, 49%), followed by status
epilepticus (n = 56, 32%). Drowning or accidental death was reported in 14 cases (8%), infections in 9 (5%),
other causes in six (3%), and unknown in ﬁve (3%). Age at death was reported for 142 of the 177 cases (80%),
with a mean age of 8.7 ± 9.8 years (SD); 73% died before the age of 10 years.
Discussion: Dravet syndrome is characterized by high epilepsy-related premature mortality and a marked young
age at death. Sudden unexpected death in epilepsy is the leading reported cause of death in DS, accounting for
nearly half of all deaths. The cause of this excess mortality remains elusive but may be explained by epilepsy
severity, as well as genetic susceptibility to SUDEP.gen Nederland — SEIN, PO B
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Dravet syndrome (DS), previously known as severe myoclonic epi-
lepsy in infancy (SMEI), is a devastating epileptic syndrome [1]. At
least 70% of cases are due to heterozygote loss-of-function mutations
in the SCN1A gene [2,3]. The estimated incidence of DS is between
1:20,000 and 1:40,000 [4–7]. Typically, seizure onset is in the ﬁrst year
of life, usually with prolonged fever- or temperature-sensitive seizures,
including generalized tonic–clonic and unilateral clonic seizures [8].
Before seizure onset, psychomotor development and EEGs are normal
[5]. Other seizure types, including myoclonus, absences, and complex
partial seizures may follow [1,8,9]. Seizures are often refractory to anti-
epileptic drug treatment [9,10]. A slowing of development becomes
apparent after the ﬁrst year of life [5]. Cognitive outcome is typically
poor, and pyramidal signs and ataxia often develop [9,11].ox
license (Long-termoutcome is dominated by prematuremortality, estimated
to affect up to 21% of thosewith DS [8,10]. A strong association between
sudden unexpected death in epilepsy (SUDEP) and DS has been sug-
gested [10,12]. SCN1A has been suggested as a possible candidate
SUDEP gene [13,14]. These suggestions predominantly rely on small
cohort studies or case reports. To improve understanding of DS prema-
ture mortality, we conducted a comprehensive literature search with a
particular emphasis on SUDEP.
2. Methods
We used the scoping reviewmethod [15] to identify and summarize
all relevant literature on DS mortality, regardless of quality or study
design of included studies.
2.1. Database search
Weconducted a comprehensive literature search of PubMed, Embase,
Webof Science, Cochrane, CENTRAL, CINAHL, PsycINFO, Academic Searchhttp://creativecommons.org/licenses/by-nc-nd/4.0/).
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syndrome”, “severemyoclonic epilepsy”, “SMEI”, “mortality”, “survivors”,
“prognosis”, and “death”. We searched all available publications up to
12 February 2016 (Appendix 1). The search strategy was developed
and conducted by two authors (SS and RDT) and a librarian.
2.2. Inclusion and exclusion criteria
Inclusion criteria were 1) title and abstract available in English,
2) humanDS case(s) (SMEI or severemyoclonic epilepsy of infancy bor-
derline (SMEB)), and 3) mortality data available for these case(s). Arti-
cles describing previously published mortality data were excluded.
References of all included articles were screened for additional eligible
papers.
2.3. Data collection
We collected data on the following: cause of death, age at death,
SCN1A testing (yes or no), and SCN1Amutation identiﬁed (yes or no).
Cause of death was categorized as 1) SUDEP, 2) status epilepticus (SE),
3) accidental (including drowning), 4) infective, 5) other, and 6) un-
known (i.e., not known or not reported). Sudden unexpected death in
epilepsy cases were classiﬁed as deﬁnite, probable, or possible. [16].Fig. 1. Flow diagram of database seThe following clinical variables in SUDEP cases were recorded (yes or
no): witnessed, from sleep, prone position, and signs of a recent seizure.
2.4. Data analysis
Descriptive statistics were used to present the results. When the
mean was calculated, standard deviation was added as a measure of
variability.
3. Results
3.1. Database search
The search yielded 676 articles and 86 meeting abstracts. Duplicate
titles were removed, leaving 427 articles and 83 meeting abstracts.
After screening titles and abstracts, 354 articles and 77 meeting ab-
stracts did not meet inclusion criteria (reasons detailed in Fig. 1).
Full texts of 73 articles and six meeting abstracts were obtained. After
reading full texts, 45 articles were excluded, yielding 28 articles and
six meeting abstracts that met our inclusion criteria. Five articles and
four meeting abstracts were excluded, as the case(s) were also de-
scribed elsewhere. After checking the references of all included articles,arch on February 12th, 2016.
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publications (23 cohorts and 7 case reports) (Appendix 2).
A total of 177 unique fatal DS cases were described (Table 1); of
these, only 30 were known to have been tested for an SCN1Amutation,
found in 28/30.
3.2. Cause of death
Causes of death for the 177 cases are shown in Fig. 2. Sudden unex-
pected death in epilepsy was the leading cause of death (n = 87, 49%)
followed by status epilepticus (n = 56, 32%). Fatal drowning and acci-
dents were described in 14 cases (8%) and fatal infections in nine
(5%). Other causes (n= 6, 3%) included (one case each): respiratory in-
sufﬁciency and generalized hypoxemia secondary to acute respiratory
distress syndrome, ketoacidosis, global ischemic brain injury, brainstem
tumor, found dead shortly after tonsillectomy, and postoperativemulti-
ple organ failure. In ﬁve cases, the cause of death was unknown or not
reported (3%).
To test whether publication bias may have increased the proportion
of SUDEP, we performed a separate analysis of cause of death in the
23 cohorts. After exclusion of all fatal case reports, the distribution of
causes of deathwas 47% SUDEP (n=81), 34% SE (n=56), 8%drowningTable 1
Data collected from the 30 included articles presenting unique DS mortality cases. Sudden une
when autopsywas reported. References are listed inAppendix II. The cause of death category ‘ot
hypoxemia secondary to acute respiratory distress syndrome, ketoacidosis, global ischemic brai
organ failure.
# Study Year Mortality
(n)
Ages
known
(n)
SCN1A
tested
(n)
SCN1A+ (n) Cause of death
SUDEP
(n)
SE
(n)
Drow
accid
1 Ogino 1989 1 1 0 0 1 0 0
2 Reniera 1990 1 1 0 0 1 0 0
3 Miyake 1991 4 0 0 0 0 3 0
4 Dravet 1992 10 9 0 0 2 2 4
5 Dooley 1995 1 1 0 0 0 0 1
6 Castro-Gagoa 1997 1 1 0 0 0 0 0
7 Perez 1999 1 0 0 0 1 0 0
8 Oguni 2001 12 6 0 0 3 7 1
9 Ceulemans 2004 1 1 1 1 0 1 0
10 Caraballo 2006 2 0 NR NR 0 0 0
11 Jansen 2006 1 1 0 0 0 0 0
12 Akiyama 2010 6 0 NR NR 1 3 0
13 Le Gala 2010 1 1 1 1 1 0 0
14 Catarino 2011 8 8 6 4 4 0 0
15 Genton 2011 5 5 NR NR 3 1 0
16 Sakauchi 2011 59 58 NR NR 31 21 6
17 Skluzacek 2011 31 31 NR NR 19 10 1
18 Brunklaus 2012 5 0 5 5 3 2 0
19 Okumura 2012 4 4 2 2 0 4 0
20 Brunklausb 2013 3 0 3 3 2 1 0
21 Friedmana 2013 1 1 1 1 1 0 0
22 Nabbouti 2013 2 2 NR NR 1 0 0
23 Wirrell 2013 2 2 NR NR 1 0 0
24 Barbac 2014 1 1 1 1 0 0 0
25 Klassena 2014 1 1 1 1 1 0 0
26 Takayama 2014 2 2 0 0 1 0 1
27 Dedea 2015 1 1 1 1 1 0 0
28 Donner 2015 6 0 5 5 6 0 0
29 Kolikondaa 2015 1 1 NR NR 1 0 0
30 Verbeek 2015 3 3 3 3 2 1 0
Total (n) 177 142 30 28 87 56 14
SUDEP = sudden unexpected death in epilepsy; SE = status epilepticus; NR = not reported; N
a Case report.
b Five of eight reported deaths were previously described and therefore not included (Brunk
c One of two mortality cases was previously described and therefore not included (Le Gal etor accident (n= 14), 5% fatal infection (n= 9), 2% other cause (n= 5),
and 3% unknown (n=5). One cohort study reported only SE cases [17].
When also excluding these four deaths, the distribution was the follow-
ing: total n= 166; 49% SUDEP (n= 81), 31% SE (n= 52), 8% drowning
or accident (n= 14), 5% fatal infection (n= 9), 3% other cause (n= 5),
and 3% unknown (n = 5).
3.3. Age at death
Age at death was reported for 142 of the 177 cases (80%). The mean
age at death was 8.7 ± 9.8 years (SD); 73% occurred before the age
of 10 years, and 93% occurred before the age of 20. The age distribu-
tion for all causes of death is shown in Fig. 3. Six cases (four SUDEP
and two drowning) were grouped into an “18+ category” with a
maximum age of 24 years [12]. We divided these cases evenly
over this age category (SUDEP 18, 20, 22, and 24 years; drowning
20 and 22 years).
3.4. Characteristics of SUDEP cases
Postmortem examinationwas reported in 12 of 87 SUDEP cases, and
autopsy was not performed in 37 cases; thus, 12 cases (14%) could bexpected death in epilepsy cases were further speciﬁed into deﬁnite and probable SUDEP
her’ included (from top to bottom) the following: respiratory insufﬁciency and generalized
n injury, brainstem tumor, found dead day after tonsillectomy, and postoperative multiple
Comments
ning or
ent (n)
Fatal
infection (n)
Other
(n)
Unknown
(n)
0 0 0 Dravet cohort children (n = 10)
0 0 0 Case report
0 0 1 Children who died at neurology
department (n = 237)
1 0 1 Dravet cohort all ages (n = 63)
0 0 0 Dravet cohort children (n = 7)
0 1 0 Case report
0 0 0 Cohort of children with refractory
epilepsy (n = 104, of which 21 DS)
1 0 0 Dravet cohort children (n = 84)
0 0 0 Dravet SCN1A+ cohort (n = 12)
1 0 1 Dravet cohort children (n = 53)
0 0 1 Dravet cohort adults (n = 14)
2 0 0 Dravet cohort all ages (n = 37)
0 0 0 Case report
3 1 0 Dravet cohort all ages, 3 post mortem
diagnosed (n = 22)
0 0 1 Dravet cohort adults (n = 24)
1 0 0 Questionnaire sent to pediatricians, max.
age 24 (n = 623)
0 1 0 Dravet cohort all ages (n = 833)
0 0 0 Dravet SCN1A+ cohort children (n = 88)
0 0 0 Dravet children with SE (n = 15)
0 0 0 Meeting abstract (n = 207, including
88 cases of Brunklaus et al., 2012)
0 0 0 Case report
0 1 Dravet cohort max. age 24 (n = 67)
0 1 0 Dravet cohort children (n = 82)
0 1 0 Dravet SCN1A+ cohort children (n = 6)
0 0 0 Case report
0 0 0 Dravet cohort adults (n = 64)
0 0 0 Case report
0 0 0 Meeting abstract; Dravet cohort all ages
(n = 34)
0 0 0 Case report
0 0 0 Dravet SCN1A+ cohort up to age of
20 (n = 77)
9 6 5
/A = not applicable.
laus et al., 2012).
al., 2014).
Fig. 2. Six categories of cause of death in 177 DS cases and percentage of cases in each category. DS = Dravet syndrome; SUDEP = sudden unexpected death in epilepsy; SE = status
epilepticus.
72 S. Shmuely et al. / Epilepsy & Behavior 64 (2016) 69–74classiﬁed as deﬁnite SUDEP, 37 (43%) as probable SUDEP, and 38 cases
(44%) could not be classiﬁed. The following SUDEP characteristics were
present when reported: six out of seven were unwitnessed (86%),
26 of 34 occurred from sleep (76%), two of three were found prone
(67%), and seven of eight cases had signs of a recent seizure (88%).
4. Discussion
Dravet syndrome is characterized by high epilepsy-related prema-
ture mortality and a marked young mean age at death. Sudden unex-
pected death in epilepsy is the leading cause of death in DS, causing
nearly half of all deaths in this condition.
Epilepsy-related deaths (SUDEP and SE) account for the vast ma-
jority of prematuremortality in DS (up to 81%). This contrasts with pre-
vious cohorts of new-onset epilepsies (up to 3%) [18,19]. In chronic
epilepsy cohorts, the proportion of epilepsy-related deaths is higher,
varying from 46 to 73% of all cases of premature mortality [20]. Even
compared with those cohorts, DS stands out with remarkably high
epilepsy-related premature mortality.
Up to a third of all deaths in DS are the results of episodes of SE. In
other epilepsy cohorts, the proportion of fatal SE is much lower; 0.2–1%
in population-based cohorts [19,21] and up to 14% in chronic cohorts
[22–24]. The age at death for SE in DS (86% ≤10 years; 98% ≤20 years)
was remarkably lower than seen in other epilepsies; 4% ≤10 years [25]
and 3% b20 years [26].
The leading cause of death in DS, SUDEP, accounts for nearly half
of overall mortality (49%). This ﬁgure contrasts with population-basedFig. 3. Age distribution for all causes of death in 142 DS cases. DS = Dravet syndrocohorts of people with epilepsy (2–4%) [21,27] and some cohorts of
people with intractable epilepsy (20–25%) [28,29]. Other studies of
chronic epilepsy cohorts show similar SUDEP proportions of overall
mortality (42–44%) [22,24], up to 50% in cohorts with chronic intracta-
ble epilepsy and learning difﬁculties [23].
Sudden unexpected death in epilepsy in DS tends to occur at a
younger age (73% before the age of 11) than in other epilepsy cohorts
(3–9% ≤10 years) [23,30–32]. In these cohorts, SUDEP risk peaks
in early adulthood (45–56% 20–40 years vs. 6% 20–40 years in DS)
[30,32,33]. Sudden unexpected death in epilepsy characteristics in DS
seem quite similar to those reported in other epilepsies [34–37], but
often, details were not reported.
High SUDEP rates in DS may be explained by epilepsy severity. The
main SUDEP risk factors, including high frequency of convulsions
and antiepileptic drug polytherapy [35–39], relate to epilepsy severity;
these factors are often seen in DS. Young age at death may also, at least
partly, be explained by epilepsy severity, as the tendency for SE and
high frequency of convulsions in those with DS seems to peak in child-
hood [40,41]. The number of convulsions often gradually decreases over
time, and SE rarely occurs after the age of 10 [40,41]. In other epilepsies,
SE appears to have a bimodal age distribution,with the highest frequen-
cy in children and the elderly [26,42], but this does not apply to the
mortality ﬁgures: despite the high frequency of SE in children, its mor-
tality in non-DS children is low, whereas in the elderly, both a high in-
cidence rate and high mortality rate of SE have been reported [25,26].
The association between DS and SUDEP is supported by animal
studies. Mutant SCN1A knock-out or knock-in mice were often foundme; SUDEP = sudden unexpected death in epilepsy; SE = status epilepticus.
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SUDEP [43–46]. Mice were found to have decreased heart rate vari-
ability (HRV) [45]. Several mice died from bradycardia at seizure offset
and from seizure-triggered ventricular ﬁbrillation [43,45]. Interictal
human DS studies demonstrated lower HRV [47] and increased QT-
dispersion [48] in DS compared with those with other epilepsies and
healthy controls suggesting an increased arrhythmia vulnerability; ictal
proof is lacking and is the subject of an ongoing project (ClinicalTrials.
gov Identiﬁer: NCT02415686).
SCN1A has been suggested as a possible candidate SUDEP gene [13,
14,49,50]. This hypothesis predominantly relies on the abovementioned
animal studies and postmortem genetic analyses of SUDEP cases [13,14,
51]. Potentially deleterious variants in the SCN1A gene have been found
in SUDEP cases without a clinical diagnosis of DS [13,14,50]. Whether
SCN1A is a ‘SUDEP gene’ is debatable, as this would require a proof
that SCN1A independently confers SUDEP risk beyond epilepsy severity.
Our ﬁndings may have been affected by differences in methodology
and reporting. Publication bias on epilepsy-related mortality reporting,
especially SUDEP, may also have played a role. Sudden unexpected
death in epilepsy, however, remained the major cause of death even
after exclusion of case reports. It is likely that more severe DS pheno-
types were included, as most cases were seen at tertiary centers. This
referral bias may have led to an overestimation of epilepsy-related
mortality. This may also apply to the time frame: most cases were iden-
tiﬁed in a period when DS was still diagnosed by strict clinical criteria
[8]. Several factors may have inﬂuenced the age distribution found.
Underdiagnosis is a recognized problem in DS. In the last 10 to 15 years,
genetic testing for DS has been widely implemented, and this has likely
led to increased diagnosis in children rather than adults, as DS is seen as
a pediatric syndrome. Awareness of DS is also recent, as it was only
described about four decades ago [1]. Adults may have thus missed
out on a diagnosis [52,53]. The reported DS population is likely to be
biased toward younger cases, thus affecting our results as most studies
describe pediatric cohorts (Table 1). The peak of deaths at young age
was, however, consistent and also seen in those cohorts with longer
follow-up into adulthood [40,54].
Another limitation includes diagnostic accuracy: clinical features of
most DS caseswere poorly described, and in themajority of cases, no in-
formation was provided whether cases had been tested for an SCN1A
mutation. Another potential limitation is that most SUDEP cases did
not have a postmortem examination.
These factors all underscore the need for further studies. Reliable
ﬁgures are crucial to inform health care professionals, individuals with
the condition, and their carers.
Future studies are warranted to conﬁrm and update these ﬁndings
and should involve long-term follow-up of large, properly genetically
detailed, DS cohorts. Preferably, nationwide genetic databases should
be used for recruitment to avoid referral bias [55] and should include
complete documentation of the full clinical DS spectrum, as well as
detailed reporting of the circumstances of death, including autopsy
reports. These studies would provide better estimates of mortality and
SUDEP frequency in people with DS. Genetic studies may elucidate the
potential role of the variety of SCN1Amutations in premature mortality
and provide markers to estimate SUDEP risks.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yebeh.2016.09.007.Acknowledgements
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